JWJuncheng Mbbs Wan

Juncheng Mbbs Wan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juncheng Mbbs Wan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sequential HAIC-TACE combined with targeted and immunotherapy in hepatocellular carcinoma: a quality improvement study

    by Juncheng Mbbs Wan, Bufu Tang, Wen Zhang, Yongjie Zhou, Chaoqiao Mbbs Jin, Caihong Mbbs Yu, Changyu Li, Wei Zhang, Zhuoyang Fan, Guowei Yang, et al.

    Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality. Emerging evidence suggests that quadruple therapy – combining hepatic artery infusion chemotherapy (HAIC), transcatheter arterial chemoembolization (TACE), targeted therapy, and immunotherapy – improves outcomes. However, few studies have directly compared this regimen with triple therapy (TACE plus targeted therapy and immunotherapy), and the optimal sequence of locoregional treatments within this regimen remains unclear. Objective: To compare the efficacy and safety of HAIC-first quadruple therapy, TACE-first quadruple therapy, and triple therapy in patients with unresectable HCC (uHCC). Materials and Methods: We retrospectively analyzed 158 patients with uHCC who received: HAIC-first quadruple therapy (HTTI, n = 61), TACE-first quadruple therapy (THTI, n = 41), or triple therapy (TTI, n = 56). Tumor response was assessed with modified RECIST; progression-free survival (PFS), overall survival (OS), and safety were compared. Results: The HTTI group achieved the highest objective response rate (ORR, 81.97%) and disease control rate (DCR, 96.72%), outperforming the THTI (ORR 73.17%, DCR 95.12%) and TTI groups (ORR 64.28%, DCR 85.71%). The median OS (mOS) was not reached in the HTTI group; the THTI group had a longer mOS (22.30 months) than the TTI group (19.00 months, P = 0.046). The median PFS (mPFS) was also longer in the HTTI group (12.90 months), compared to the THTI (10.40 months, P = 0.042) group and TTI groups (9.30 months, P < 0.001). Quadruple therapy increased grade 1 and 2 hypoalbuminemia, thrombocytopenia, and hand-foot syndrome, but grade 3 and 4 toxicities were similar across groups. Conclusion: Quadruple therapy demonstrates superior efficacy compared to triple therapy for uHCC. Initiating treatment with HAIC followed by TACE appears more effective than the reverse sequence and merits prospective validation.


  • Open Access

    Application of ultrasound-guided intranodal lymphangiography in the diagnosis and treatment of chylous ascites after abdominal surgery

    by Juncheng Wan, Wen Zhang, Caihong Yu, Changyu Li, Yongjie Zhou, Wei Zhang, Zhuoyang Fan, Chaoqiao Jin, Xudong Qu

    Purpose: Chylous leakage is a serious and challenging postoperative complication. The purpose of this study was to explore the application of ultrasound-guided intranodal lymphangiography in the diagnosis and treatment of chylous ascites following abdominal surgery.Material and methods: Ten patients with chylous ascites after abdominal surgery after ineffective conservative treatment such as low-fat diet, parenteral nutrition, and negative pressure drainage were included in this single-center retro­spective study. Of these 10 patients, 9 developed chylous ascites after liver surgery, and 1 after a radical gastrectomy.Results: Lymphangiography was successfully performed in all 10 patients. The average dosage of lipiodol used was 4.5 ml (range 3.5-7.0 ml). No procedure-related complications were observed after excluding unrelated factors. During lymphangiography, lipiodol leakage was directly observed in 3 cases, and in the other 5 cases, it was detected through abdominal computed tomography post-lymphangiography. Chylous ascites resolved solely through lymphangiography in 6 patients without requiring additional surgical intervention.Conclusions: Lymphangiography may help identify leakage sites in patients with chylous ascites unresponsive to conservative treatment and could potentially be effective in treating chylous ascites following abdominal surgery.